Kronos Bio Q3 2023 Earnings Report $0.82 -0.01 (-0.61%) As of 03/28/2025 04:00 PM Eastern Earnings HistoryForecast Kronos Bio EPS ResultsActual EPS-$0.54Consensus EPS -$0.51Beat/MissMissed by -$0.03One Year Ago EPSN/AKronos Bio Revenue ResultsActual Revenue$0.92 millionExpected Revenue$2.50 millionBeat/MissMissed by -$1.58 millionYoY Revenue GrowthN/AKronos Bio Announcement DetailsQuarterQ3 2023Date11/13/2023TimeN/AConference Call ResourcesKRON Earnings History Remove Ads Kronos Bio Earnings HeadlinesKronos Bio Reports 2024 Financial ResultsMarch 27 at 12:06 AM | tipranks.comKronos Bio Full Year 2024 Earnings: US$1.43 loss per share (vs US$1.95 loss in FY 2023)March 20, 2025 | finance.yahoo.comGame Over for Tesla?Tesla is down 50% from its high... Our research indicates investors are waking up to the fact that Tesla is no longer Musk's #1 priority. His real goal is political power - and his private AI firm xAI. He recently bought over $1 billion worth of AI chips from NVIDIA... And is about to spend $5 billion on yet another data center for xAI.March 29, 2025 | Behind the Markets (Ad)Kronos Bio reports Q4 EPS (43c) vs. (43c ) last yearMarch 19, 2025 | markets.businessinsider.comKronos Bio Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 18, 2025 | globenewswire.comKronos Bio Insider Ups Holding By 36% During YearFebruary 23, 2025 | uk.finance.yahoo.comSee More Kronos Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kronos Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kronos Bio and other key companies, straight to your email. Email Address About Kronos BioKronos Bio (NASDAQ:KRON), a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.View Kronos Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
